InMed Pharmaceuticals Inc. - Common Shares, no par value (INM)
CUSIP: 457637601
Q1 2023 13F Holders as of 31 Mar 2023
- Type / Class
- Equity / Common Shares, no par value
- Shares outstanding
- 804,525
- Total 13F shares
- 100,918
- Share change
- -14,910
- Total reported value
- $109,292
- Price per share
- $1.08
- Number of holders
- 12
- Value change
- -$123,996
- Number of buys
- 6
- Number of sells
- 3
Quarterly Holders Quick Answers
What is CUSIP 457637601?
CUSIP 457637601 identifies INM - InMed Pharmaceuticals Inc. - Common Shares, no par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 457637601:
Top shareholders of INM - InMed Pharmaceuticals Inc. - Common Shares, no par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13F
|
Company |
12%
|
97,163
|
$196,269 | — | 31 Dec 2022 | |
| Virtu Financial LLC |
13F
|
Company |
2.2%
|
17,724
|
$36,000 | — | 31 Dec 2022 | |
| Bruce Colwill |
3/4/5
|
CFO |
—
class O/S missing
|
11,515
|
$10,294 | — | 24 Jan 2022 | |
| UBS Group AG |
13F
|
Company |
0.1%
|
831
|
$1,679 | — | 31 Dec 2022 | |
| TD Waterhouse Canada Inc. |
13F
|
Company |
0.01%
|
85
|
$252 | — | 31 Dec 2022 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.01%
|
50
|
$101 | — | 31 Dec 2022 | |
| AllSquare Wealth Management LLC |
13F
|
Company |
0%
|
21
|
$42 | — | 31 Dec 2022 | |
| Federation Des Caisses Desjardins du Quebec |
13F
|
Individual |
0%
|
19
|
$38 | — | 31 Dec 2022 | |
| NATIONAL BANK OF CANADA /FI/ |
13F
|
Company |
0%
|
7
|
$14 | — | 31 Dec 2022 | |
| Advisory Services Network, LLC |
13F
|
Company |
0%
|
6
|
$12 | — | 31 Dec 2022 | |
| TCI Wealth Advisors, Inc. |
13F
|
Company |
0%
|
5
|
$10 | — | 31 Dec 2022 | |
| GABLES CAPITAL MANAGEMENT INC. |
13F
|
Company |
0%
|
1
|
$2 | — | 31 Dec 2022 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
1
|
$2 | — | 31 Dec 2022 | |
| Catherine Sazdanoff |
3/4/5
|
Director |
—
class O/S missing
|
29,091
|
— | — | 29 Dec 2021 | |
| Adam D. Cutler |
3/4/5
|
Director |
—
class O/S missing
|
16,122
|
— | — | 24 Jan 2022 | |
| Mr. William J. Garner |
3/4/5
|
Director |
—
class O/S missing
|
16,122
|
— | — | 24 Jan 2022 | |
| Ms. Sarah Li |
3/4/5
|
VP Accounting & Controller |
—
class O/S missing
|
4,002
|
— | — | 16 Dec 2022 |
Institutional Holders of InMed Pharmaceuticals Inc. - Common Shares, no par value (INM) as of Q1 2023
As of 31 Mar 2023,
InMed Pharmaceuticals Inc. - Common Shares, no par value (INM) was held by
12 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
100,918 shares.
The largest 10 holders included
RENAISSANCE TECHNOLOGIES LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, UBS Group AG, BANK OF AMERICA CORP /DE/, BlackRock Inc., ADVISOR GROUP HOLDINGS, INC., AllSquare Wealth Management LLC, Federation des caisses Desjardins du Quebec, NATIONAL BANK OF CANADA /FI/, and Advisory Services Network, LLC.
This page lists
12
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2023 vs Q4 2022 Across Filers
Q4 2022 holders
11
Q1 2023 holders
12
Holder diff
1
| Investor | Q4 2022 Shares | Q1 2023 Shares | Share Diff | Share Chg % | Q4 2022 Value $ | Q1 2023 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.